Vigabatrin, Lamotrigine, Topiramate and Serum Carnitine Levels

Pediatric Neurology

Volumn 39, Issue 1, 2008, Pages 18-21

  Zelnik, Nathanel ^a   Isler, Naomi ^a   Goez, Helly ^b   Shiffer, Mirta ^a   David, Miriam ^a   Shahar, Eli ^c  

^a CARMEL MEDICAL CENTER   (Israel)

^b Child Neurodevelopment Center   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; LAMOTRIGINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ANALYTICAL PARAMETERS; ARTICLE; BLOOD LEVEL; CARNITINE DEFICIENCY; CHILD; CONTROLLED STUDY; DRUG EFFECT; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL;

ADOLESCENT; ANTICONVULSANTS; CARNITINE; CHILD; CHILD, PRESCHOOL; FEMALE; FRUCTOSE; HUMANS; INFANT; MALE; PROSPECTIVE STUDIES; SEIZURES; TRIAZINES; VIGABATRIN;

EID: 44849091279     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2008.03.005     Document Type: Article

References (23)

1. Ohtani Y., Fumio E., and Matsuda I. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 101 (1982) 782-785
2. Opala G., Winter S., Vance C., Vance H., Hutchison H.T., and Linn L.S. The effect of valproic acid on plasma carnitine levels. Am J Dis Child 145 (1991) 999-1001
3. Thom H., Carter P.E., Cole G.F., and Stevenson K.L. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs. Dev Med Child Neurol 33 (1991) 795-802
4. Van Wouve J.P. Carnitine deficiency during valproic acid treatment. Int J Vitam Nutr Res 65 (1995) 211-214
5. Coulter D.L. Carnitine, valproate and toxicity. J Child Neurol 6 (1991) 7-14
6. Coulter D.L. Carnitine deficiency in epilepsy: Risk factors and treatment. J Child Neurol 10 Suppl. 2 (1995) S32-S39
7. Hug G., McGraw C.A., Bates S.R., and Landrigan E.A. Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children. J Pediatr 119 (1991) 799-802
8. Zelnik N., Fridkis I., and Gruener N. Reduced carnitine and antiepileptic drugs: Cause relationship or co-existence?. Acta Paediatr 84 (1995) 93-95
9. Riva R., Albani F., Gobbi G., Santucci M., and Baruzzi A. Carnitine disposition before and during valproate therapy in patients with epilepsy. Epilepsia 34 (1993) 184-187
10. Castro-Gago M., Eiris-Punal J., Novo-Rodriguez M.I., Couceiro J., Camina F., and Rodriguez-Segade S. Serum carnitine levels in epileptic children before and during treatment with valproic acid, carbamazepine, and phenobarbital. J Child Neurol 13 (1998) 546-549
11. Coppola G., Epifanio G., Auricchio G., Federico R.R., Resicato G., and Pascotto A. Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. Brain Dev 28 (2006) 358-365
12. De Vivo D.C., and Tein I. Primary and secondary disorders of carnitine metabolism. Int Pediatr 5 (1990) 134-141
13. McGarry J.D., and Foster D.W. Improved and simplified radioisotopic assay for the determination of free and esterified carnitine. J Lipid Res 17 (1976) 277-281
14. Verrotti A., Greco R., Morgese G., and Chiarelli F. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. Int J Clin Lab Res 29 (1999) 36-40
15. Beghi E., Bizzi A., Codegoni A.M., Trevisian D., and Torri W. Valproate, carnitine metabolism and biochemical indicators of liver function. Collaborative Group of the Study of Epilepsy. Epilepsia 31 (1990) 346-352
16. Morita J., Yuge K., and Yoshino M. Hypocarnitinemia in the handicapped individuals who receive a polypharmacy of antiepileptic drugs. Neuropediatrics 17 (1986) 203-205
17. De Vivo D.C., Bohan T.P., Coulter D.L., et al. L-carnitine supplementation in childhood epilepsy: Current perspectives. Epilepsia 39 (1998) 1216-1225
18. Seven M., Cengiz M., Tuzgen S., and Iscan M.Y. Plasma carnitine levels in children with Down syndrome. Am J Hum Biol 13 (2001) 721-725
19. Pons R., and De Vivo D.C. Primary and secondary carnitine deficiency syndromes. J Child Neurol 10 Suppl (1995) 2S8-24
20. Millington D.S., Bohan T.P., Roe C.R., Yergey A.L., and Liberato D.J. Valproylcarnitine: A novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry. Clin Chim Acta 145 (1985) 69-76
21. Matsuda I., Ohtani Y., and Ninomiya N. Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy. J Pediatr 109 (1986) 131-134
22. Haas R., Stumpf D.A., Parks J.K., and Eguren L. Inhibitory effects of sodium valproate on oxidative phosphorylation. Neurology 31 (1981) 1473-1476
23. Fung E.L.W., Tang N.L.S., Ho C.S., Lam C.W.K., and Fok T.F. Carnitine level in Chinese epileptic patients taking sodium valproate. Pediatr Neurol 28 (2003) 24-27